From VICE: “In a popular and public move, the United Statesā Federal Drug Administration recently approvedĀ intranasal esketamine, one of the components of the psychedelic ketamine, for treatment-resistant depression. The nasal sprayĀ costs nearly $900 per doseāor roughly $7,000 for the first month of treatment, and each treatment takes at leastĀ two hoursĀ in a clinic. (It has yet to be decided how much of the cost insurance plans will cover.)
Esketamine can be unwieldy to use and carries a number of significant potential side effects. Shockingly, it wasĀ no better than placeboĀ in two of the three short-term Phase-III studies submitted to the FDA for approval.
But the biggest problem at hand is not the drug itself. Itās the fact that instead of representing aĀ revolution in mental health treatment, as it has been touted to do, esketamine is not a breakthrough at all. Itās just a way for pharmaceutical company Johnson & Johnson to make a significant profit off gullible insurance companies and vulnerable patients.”